Breaking Barriers: Studying Fracture Healing in the BONES Program.


Journal

Journal of orthopaedic trauma
ISSN: 1531-2291
Titre abrégé: J Orthop Trauma
Pays: United States
ID NLM: 8807705

Informations de publication

Date de publication:
01 03 2021
Historique:
accepted: 09 12 2020
entrez: 15 2 2021
pubmed: 16 2 2021
medline: 22 6 2021
Statut: ppublish

Résumé

The Bioventus Observational Noninterventional EXOGEN Studies (BONES) Program includes 3 concurrent studies designed to estimate the incidence of fracture nonunions in patients treated with the EXOGEN Ultrasound Bone Healing System compared with those receiving standard fracture care. This article outlines the design and methodology within the fifth metatarsal fracture study; similar approaches are taken in the second and third BONES Program studies, which examine nonunions of the tibia and scaphoid. The BONES Program is an external comparator design and incorporates several unique, fit-for-purpose components to strengthen the approach and allow it to be submitted to the US Food and Drug Administration (FDA) to be considered for a label expansion. BONES consisted of 2 cohorts: (1) EXOGEN-treated patients recruited into a patient registry and (2) comparator patients from a large administrative health claims database. The study used International Classification of Diseases, Tenth Revision, nonunion diagnosis codes reported by the treating clinician for the primary outcome measure. Many data sources (medical and billing records, patient-reported health data, usage data from the device itself, and commercial product complaint system) were used on the registry side, alongside insurance claims data to source the external comparator cohort, to achieve broader understanding of factors predisposing patients to the development of nonunions. In step with the FDA's increasing acceptance of real-world evidence for use in regulatory decision making and coupled with the infeasibility of a randomized clinical trial in this setting, the innovative study design of the BONES Program allowed for both an evaluation of the effect of EXOGEN in mitigating nonunions in a real-world setting and an assessment of the patient experience with EXOGEN treatment.

Identifiants

pubmed: 33587543
doi: 10.1097/BOT.0000000000002035
pii: 00005131-202103001-00006
doi:

Types de publication

Journal Article Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

S22-S27

Informations de copyright

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Références

Amin S, Achenbach SJ, Atkinson EJ, et al. Trends in fracture incidence: a population-based study over 20 years. J Bone Miner Res. 2014;29:581–589.
Ekegren CL, Edwards ER, de Steiger R, et al. Incidence, Costs and predictors of nonunion, delayed union and mal-union following long bone fracture. Int J Environ Res Public Health. 2018;15:2845.
Brinker MR, Hanus BD, Sen M, et al. The devastating effects of tibial nonunion on health-related quality of life. J Bone Joint Surg Am 2013;95:2170–1276.
Majeed H, Karim T, Davenport J, et al. Clinical and patient-reported outcomes following Low Intensity Pulsed Ultrasound (LIPUS, Exogen) for established post-traumatic and post-surgical nonunion in the foot and ankle. Foot Ankle Surg. 2020;26:405–411.
Perumal V, Roberts CS. Factors contributing to nonunion of fractures. Curr Orthop. 2007;21:258–261.
Kaiser PB, Guss D, DiGiovanni CW. Stress fractures of the foot and ankle in athletes. Foot Ankle Orthopaed. 2018;3:247301141879007.
Weatherford B. Metatarsal fractures. 2020. [ www.orthobullets.com ]. Available at: http://www.orthobullets.com/foot-and-ankle/7032/metatarsal-fractures . Accessed October 19, 2020.
Griffin XL, Smith N, Parsons N, et al. Ultrasound and shockwave therapy for acute fractures in adults. Cochrane Database Syst Rev. 2014:CD008579. doi: 10.1002/14651858.CD008579.
AETNA. Bone Growth Stimulators. 2021. [ www.aetna.com ]. Available at: http://www.aetna.com/cpb/medical/data/300_399/0343.html . Accessed January 6, 2021.
BlueCross BlueShield BlueCare Network of Michigan. Bone Growth Stimulation: Ultrasound Accelerated Fracture Healing Device. 2020. [ www.bcbsm.com ]. Available at: https://www.bcbsm.com/amslibs/content/dam/public/mpr/mprsearch/pdf/2030582.pdf . Accessed January 6, 2021.
US Food and Drug Administration (FDA). Framework for the FDA's real world evidence program. 2018. [ www.fda.gov ]. Available at: https://www.fda.gov/media/120060/download . Accessed May 16, 2020.
Boudreau DM, Yu O, Spangler L, et al. Accuracy of ICD-9 codes to identify nonunion and malunion and developing algorithms to improve case-finding of nonunion and malunion. Bone. 2013;52:596–601.
Hernandez RK, Do TP, Critchlow CW, et al. Patient-related risk factors for fracture-healing complications in the United Kingdom general Practice research database. Acta Orthop. 2012;83:653–660.
Zura R, Xiong Z, Einhorn T, et al. Epidemiology of fracture in 18 human bones. JAMA Surg. 2016;151:e162775.
Irwin DE, Kelly K, Winer I, et al. Methodologies for validation of diagnoses in real-world data: BONES–a case study. J Ortho Trauma. 2021;35 (suppl 1): S28–S32.
Chronic conditions data warehouse (CCDW). 2020. [ www.ccwdata.org ]. Available at: https://www2.ccwdata.org/web/guest/home/ . Accessed October 16, 2020.
Rubin D. For objective causal inference, design trumps analysis. Annappl Stat. 2008;2:808–840.
Campbell G, Yue LQ. Statistical innovations in the medical device world sparked by the FDA. J Biopharm Stat. 2016;26:3–16.
Yue LQ. Regulatory considerations in the design of comparative observational studies using propensity scores. J Biopharm Stat. 2012;22:1272–1279.
Mahendraratnam N, Mercon K, Eckert J, et al. Adding real-world evidence to a totality of evidence approach for evaluating marketed product effectiveness. 2019. [ www.healthpolicy.duke.edu ]. Available at: https://healthpolicy.duke.edu/publications/adding-real-world-evidence-totality-evidence-approach-evaluating-marketed-product . Accessed October 19, 2020.
Mahendraratnam N, Eckert J, Mercon K, et al. Understanding the need for non-interventional studies using secondary data to generate real-world evidence for regulatory decision making and demonstrating their credibility. 2019. [ https://healthpolicy.duke.edu ]. Available at: https://healthpolicy.duke.edu/publications/understanding-need-non-interventional-studies-using-secondary-data-generate-real-world . Accessed October 19, 2020.
Krumholz H. Opinion: it's your right to see your medical records. It shouldn't be this hard to do. 2020. [ www.npr.org ]. Available at: https://www.npr.org/sections/health-shots/2019/08/28/754725843/opinion-its-your-right-to-see-your-medical-records-it-shouldn-t-be-this-hard-to- . Accessed October 19, 2020.
Zura R, Irwin DE, Mack CD. Real-world evidence: a primer. J Ortho Trauma. 2021; 35 (suppl 1): S1–S5.

Auteurs

Christina D Mack (CD)

IQVIA Real-World Solutions, Durham, NC.

Alessandra Pavesio (A)

Research & Development, Bioventus, Durham, NC.

Kim Kelly (K)

Research & Development, Bioventus, Durham, NC.

Debra E Irwin (DE)

IBM Watson Health, Wynnewood, PA.

Greg Maislin (G)

Biomedical Statistical Consulting, Wynnewood, PA; and.

John Jones (J)

Research & Development, Bioventus, Durham, NC.

Tawana Wester (T)

Research & Development, Bioventus, Durham, NC.

Robert Zura (R)

Department of Orthopaedics, Louisiana State University Health Sciences Center, New Orleans, LA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH